Nestlé deepens skin health investment with $1.4bn dermal filler deal


By Natalie Mortimer, N/A

May 28, 2014 | 2 min read

Nestlé has taken a major step in developing its Skin Health S.A arm after acquiring all rights to popular dermal fillers Restylane, Perlane, Emervel, Sculptra, and Dysport for $1.4 billion in cash.

The move, which is subject to regulatory approval, will see Nestlé Skin Health gain the full rights from Canadian firm Valeant Pharmaceuticals International to commercialise the products in the US and Canada.

"With this deal we have acquired key strategic assets to extend Nestlé's activities in the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products," said Nestlé chairman Peter Brabeck-Letmathe.

The foundation for the company is set to be Galderma, the 50/50 joint venture with L'Oréal, which will become fully-owned by Nestlé.

Bübchen, Nestlé’s existing infant skincare business will be merged into the new entity once the acquisition of Galderma is cleared.


More from Nestle

View all


Industry insights

View all
Add your own content +